График акции Nuvectis Pharma, Inc.
Расширенный график
Простой график
О компании Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. подробнее| IPO date | 2022-02-04 |
|---|---|
| ISIN | US67080T1088 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.nuvectis.com |
| Цена ао | 8.75 |
| Изменение цены за день: | +1.48% (9.78) |
|---|---|
| Изменение цены за неделю: | +18.86% (8.35) |
| Изменение цены за месяц: | +12.15% (8.85) |
| Изменение цены за 3 месяца: | +75.98% (5.64) |
| Изменение цены за полгода: | +50.38% (6.6) |
| Изменение цены за год: | +54.84% (6.41) |
| Изменение цены за 3 года: | +1.9% (9.74) |
| Изменение цены с начала года: | +111.62% (4.69) |
|
|
Недооценка
|
Эффективность
|
|||||||||||||||||||||||||||||||||||||
Дивиденды
|
Долг
|
Импульс роста
|
|||||||||||||||||||||||||||||||||||||
| Институционалы | Объем | Доля, % |
|---|---|---|
| Blackrock Inc. | 387891 | 2.18 |
| Vanguard Group Inc | 294283 | 1.66 |
| Baldwin Brothers, Inc. | 142040 | 0.8 |
| Geode Capital Management, LLC | 131657 | 0.74 |
| State Street Corporation | 118279 | 0.67 |
| Northern Trust Corporation | 61574 | 0.35 |
| Renaissance Technologies, LLC | 51800 | 0.29 |
| Millennium Management LLC | 34011 | 0.19 |
| Forbes, J.M. & Company | 34000 | 0.19 |
| GSA Capital Partners LLP | 27313 | 0.15 |
| Руководитель | Должность | Оплата | Год рождения |
|---|---|---|---|
| Mr. Ron Bentsur M.B.A. | Co-Founder, Chairman, CEO & President | 1.12M | 1966 (59 лет) |
| Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive VP, Chief Scientific & Business Officer | 705.5k | 1967 (58 лет) |
| Mr. Shay Shemesh | Co-Founder, Executive VP, Chief Development & Operations Officer | 705.5k | 1984 (41 год) |
| Mr. Michael Carson CPA | Vice President of Finance | N/A | 1976 (49 лет) |
Адрес: United States, Fort Lee. NJ, 1 Bridge Plaza - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.nuvectis.com
Сайт: https://www.nuvectis.com
